6th October 2020
Daniel Pfund, Senior Financial Analyst
Roche presented new data from a two-year study in multiple sclerosis patients. The good news is that 75% of MS patients who have relapsed in the past have been symptom-free for two years after treatment with Roche’s Ocrevus. Ocrevus is the first and only drug approved for the treatment of both the progressive form of multiple sclerosis and relapsing patients. Roche has disclosed that more than 170’000 people are treated globally with Ocrevus. In addition, Roche has demonstrated that the benefit/risk profile of the drug is still favorable after seven years of treatment.